Coronado is a biopharmaceutical company focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. Coronado's two principal pharmaceutical product candidates are initially targeted for clinical development for inflammatory bowel disease, multiple sclerosis and acute myeloid leukemia.
February 6, 2014:
December 20, 2013:
December 12, 2013:
December 9, 2013:
CNDO Announces IND Submission for TSO for the Treatment of Moderate to Severe Chronic Plaque PsoriasisCORONADO IN THE NEWS
April 23, 2013:
The Hygiene Hypothesis: Too Clean for Our Own Good?
By: Chris Leach at Insulin Nation
April 8, 2013:
TSO (Trichuris suis ova or CNDO-201) is a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis.
CNDO-109 is a biologic that activates natural killer (NK) cells for the treatment of acute myeloid leukemia (AML) and solid tumors.
ONGOING CLINICAL TRIALS
Click here for more clinical trial information.